Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.

Item

http://www.wikidata.org/entity/Q45991665

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Comparison of dual-color in-si ...... mplification in breast cancer.

@en

Comparison of dual-color in-si ...... mplification in breast cancer.

@nl

type

Item

label

Comparison of dual-color in-si ...... mplification in breast cancer.

@en

Comparison of dual-color in-si ...... mplification in breast cancer.

@nl

prefLabel

Comparison of dual-color in-si ...... mplification in breast cancer.

@en

Comparison of dual-color in-si ...... mplification in breast cancer.

@nl

P1476

Comparison of dual-color in-si ...... mplification in breast cancer.

@en

P2093

Futoshi Akiyama

http://www.w3.org/2001/XMLSchema#string

Masaaki Matsuura

http://www.w3.org/2001/XMLSchema#string

Rie Horii

http://www.w3.org/2001/XMLSchema#string

Takuji Iwase

http://www.w3.org/2001/XMLSchema#string

Yoshinori Ito

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens

HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

P2888

s12282-012-0436-0

P304

598-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12282-012-0436-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1035979343

http://www.w3.org/2001/XMLSchema#string

P698

23307494

http://www.w3.org/2001/XMLSchema#string